1
|
Borboa-Olivares H, Estrada-Gutierrez G, Martinez-Portilla RJ, Espino-y-Sosa S, Flores-Pliego A, Espejel-Nuñez A, Camacho-Arroyo I, Solis-Paredes JM, Villafan-Bernal JR, Torres-Torres J. Impact of Protease Inhibitor-Based Highly Active Antiretroviral Therapy on Fetal Subcutaneous Fat Tissue in HIV-Pregnant Women in a Middle-Income Country. Viruses 2023; 16:10. [PMID: 38275945 PMCID: PMC10818469 DOI: 10.3390/v16010010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/17/2023] [Accepted: 12/18/2023] [Indexed: 01/27/2024] Open
Abstract
BACKGROUND HIV infection continues to be a global public health challenge, affecting approximately 1.7 million reproductive-aged women. Protease inhibitor-based highly active antiretroviral therapy (PI-HAART) has significantly reduced the risk of vertical transmission of HIV from mother to child. Nevertheless, concerns linger regarding the long-term effects, particularly on body composition, notably subcutaneous fat tissue (SFT). Although HIV-associated lipodystrophy syndrome (LS) has been well documented in adults and older children, its impact on fetuses exposed to PI-HAART remains underexplored. This study aims to evaluate SFT in the fetuses of HIV-pregnant women exposed to PI-HAART, assessing the potential clinical implications. METHODS We conducted a comparative study between HIV-pregnant women receiving PI-HAART and an HIV-negative control group. Fetometry measurements were obtained via 3D ultrasound. SFT in the fetal arm and thigh segments was assessed. Data were analyzed using lineal multivariate regression and receiver-operating characteristics (ROC)-curve analysis. RESULTS Fetuses exposed to PI-HAART exhibited a significant reduction in subcutaneous fat, particularly in the proximal third-middle union of the femur (coefficient: -2.588, p = 0.042). This reduction was correlated with lower newborn serum glucose levels (65.7 vs. 56.1, p = 0.007; coefficient: -1.277, p = 0.045). CONCLUSIONS Our study sheds light on the connection between PI-HAART, fetal subcutaneous fat, and neonatal health. These findings might reveal the long-lasting effects of PI-HAART on newborns and children's well-being. Our results emphasize the need for a more balanced approach to managing pregnant women with HIV in developing countries and open new venues for research on the impact of intrauterine PI-HAART exposure on energy metabolism and fetal programming.
Collapse
Affiliation(s)
- Hector Borboa-Olivares
- Community Interventions Research Branch, Instituto Nacional de Perinatología, Mexico City 11000, Mexico
| | | | - Raigam Jafet Martinez-Portilla
- Clinical Research Branch, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City 11000, Mexico (S.E.-y.-S.); (J.M.S.-P.)
| | - Salvador Espino-y-Sosa
- Clinical Research Branch, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City 11000, Mexico (S.E.-y.-S.); (J.M.S.-P.)
| | - Arturo Flores-Pliego
- Department of Immunobiochemistry, Instituto Nacional de Perinatología, Mexico City 11000, Mexico; (A.F.-P.); (A.E.-N.)
| | - Aurora Espejel-Nuñez
- Department of Immunobiochemistry, Instituto Nacional de Perinatología, Mexico City 11000, Mexico; (A.F.-P.); (A.E.-N.)
| | - Ignacio Camacho-Arroyo
- Unidad de Investigación en Reproducción Humana, Instituto Nacional de Perinatología-Facultad de Química, Universidad Nacional Autónoma de México, Mexico City 11000, Mexico;
| | - Juan Mario Solis-Paredes
- Clinical Research Branch, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City 11000, Mexico (S.E.-y.-S.); (J.M.S.-P.)
| | - Jose Rafael Villafan-Bernal
- Laboratory of Immunogenomics and Metabolic Diseases, Instituto Nacional de Medicina Genomica, Mexico City 14610, Mexico;
| | - Johnatan Torres-Torres
- Clinical Research Branch, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City 11000, Mexico (S.E.-y.-S.); (J.M.S.-P.)
| |
Collapse
|
2
|
Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. Orphanet J Rare Dis 2019; 14:177. [PMID: 31300002 PMCID: PMC6626409 DOI: 10.1186/s13023-019-1141-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Accepted: 06/25/2019] [Indexed: 11/30/2022] Open
Abstract
Background Although metreleptin replacement therapy was shown to improve metabolic alterations in lipodystrophic syndromes, patients’ adherence and satisfaction with treatment have never been evaluated. The 20 patients with lipodystrophic syndromes participating in the French compassionate program of metreleptin therapy filled in a self-questionnaire including an Adherence Evaluation Test, the Treatment Satisfaction Questionnaire for Medication (TSQM®-vII), and items about physical appearance. Results 15 patients were women, median age was 32.5 years (IQT 25–75 (16.2;49.5), 18 had diabetes. Adherence with metreleptin (one daily subcutaneous injection) was poor in 25%, excellent in 25% and acceptable in 50% of patients. On a 0-to-100 scale, patients’ satisfaction scores reached 66.7 (52.1;81.2) for effectiveness, 55.6 (44.4;66.7) for ease/comfort of use, and 83.3 (52.1;83.3) for global satisfaction with metreleptin therapy. Self-reported side effects were frequent injection site reactions 100 (79.2;100). Satisfaction scores did not differ in patients with partial (n = 10) or generalized (n = 10) lipodystrophic syndromes, did not correlate with metabolic improvement, but were significantly higher in compliant patients with fewer side effects. Morphological appearance was reported improved under metreleptin therapy in 13 among 17 patients. Conclusions Metreleptin increases health self-perception and decreases morphotype-associated stigmatization in most patients with lipodystrophic syndromes, but poor comfort of use and local side effects weaken adherence.
Collapse
|
3
|
Zhang Z, Hamatake R, Hong Z. Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development. ACTA ACUST UNITED AC 2016; 15:121-34. [PMID: 15266894 DOI: 10.1177/095632020401500302] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Highly active antiretroviral therapy (HAART) has significantly reduced the number of deaths caused by AIDS. However, the antiviral efficacy of HAART comprising protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) is frequently accompanied by a decrease in patients' quality of life. PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing schedules and undesirable side effects. The current trend is to switch from PI-based to PI-sparing regimens consisting of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and NRTIs. Despite some encouraging results from NNRTI-containing therapies, two major concerns in using the currently available NNRTIs remain: 1) low genetic barrier to the emergence of resistance and 2) cross-resistance due to single mutations that often render the whole class of NNRTIs ineffective. Clearly, new and improved NNRTIs are needed to address these concerns.
Collapse
Affiliation(s)
- Zhijun Zhang
- Drug Discovery, Valeant Pharmaceuticals International, Costa Mesa, Calif., USA.
| | | | | |
Collapse
|
4
|
Yang Y, Wilder-Smith A, Panchalingam A, Tha NO, Paton NI. Changes in Body Fat Measured by DEXA in Patients Taking Different Formulations of Stavudine. HIV CLINICAL TRIALS 2015; 6:337-43. [PMID: 16452067 DOI: 10.1310/9fj9-k45e-a1r8-7wre] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Lipoatrophy is a frequent complication of chronic stavudine therapy. Stavudine extended release formulation (stavudine ER) gives lower peak and higher trough levels than the immediate release formulation (stavudine IR), and we hypothesized that the lower peak might result in less lipoatrophy. OBJECTIVE To compare the rate of peripheral lipoatrophy between patients taking stavudine ER and stavudine IR. METHOD Body composition was measured by dual energy X-ray absorptiometry (DEXA) every 6 months for 18 months in 29 patients taking either stavudine ER or IR as part of a randomized controlled clinical trial. RESULTS DEXA fat measurements did not differ between the ER and IR groups at baseline, after a median of 32 months on stavudine-containing treatment. Over the 18 months of follow-up in the whole cohort limb fat decreased by a mean of 0.29 +/- 0.50 kg (p = .01) and leg fat percent decreased by a mean of 1.23% +/- 1.92% (p = .001), whereas trunk fat and trunk-to-limb fat percent ratio did not change significantly. There was no significant difference between the ER and IR groups in the rate of change of any of the fat parameters. At study completion, the proportion of patients with clinical lipodystrophy was similar in the stavudine ER and stavudine IR groups (67% and 64%, respectively; p = .893). CONCLUSION Stavudine ER does not appear to cause less peripheral lipoatrophy.
Collapse
Affiliation(s)
- Yong Yang
- Infectious Disease Research Centre, Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
| | | | | | | | | |
Collapse
|
5
|
Yang Y, Yap M, Oo Tha N, Paton NI. Objective Assessment of Facial Lipoatrophy Changes in a Cohort of HIV-Infected Patients Taking Combination Antiretroviral Therapy. HIV CLINICAL TRIALS 2015; 9:399-406. [DOI: 10.1310/hct0906-399] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
6
|
Jin Y, Liu Z, Chen X, Wang X, Wang D, Jiang Z, Liu Y, Wang J, Zou W, Guo H, Xu L. Survival of people living with HIV after treatment with traditional Chinese medicine in Henan province of China: a retrospective cohort study. J TRADIT CHIN MED 2014; 34:430-6. [PMID: 25185360 DOI: 10.1016/s0254-6272(15)30042-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVE To provide survival estimates of people living with human immunodeficiency virus (PLHIV) after treatment with Traditional Chinese Medicine (TCM) in rural China, to identify the prognostic factors at enrollment, and to explore the effectiveness ofTCM in treating PLHIV. METHODS PLHIV who enrolled in national TCM HIV treatment trial program in October 2004 were analyzed in this study and followed up to October 2010. Survival time was estimated by the Kaplan-Meier curve and hazard ratios, and identifying prognostic factors were computed through Cox proportional hazard models. RESULTS A total of 1666 PLHIV were included with 102 591 person-months of follow-up. Overall, 312 (18.7%) patients died. The total mortality rate over the study period was 3.6 per 100 person-years, which was lower than the worldwide rate. The cumulative survival rate was 95.9% at 1 year [95% confidence interval (CI) (94.8-96.8)] and 80.4% at 6 years [95% CI (78.4-82.3)]. Elevated death risks emerged among males, older individuals, and those with lower CD4+ T-cell counts. CONCLUSION TCM could increase survival and lengthen the life span of PLHIV in Henan province of China, as shown by our retrospective cohort study. Factors such as sex, age, education, and CD4+ T-cell counts correlated to survival. However, retrospective cohorts bias the data, so more prospective studies should be performed to confirm our primary results.
Collapse
|
7
|
Duracinsky M, Leclercq P, Herrmann S, Christen MO, Dolivo M, Goujard C, Chassany O. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis 2014; 14:474. [PMID: 25178390 PMCID: PMC4160543 DOI: 10.1186/1471-2334-14-474] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Accepted: 08/19/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Facial lipoatrophy is a frequently reported condition associated with use of antiretroviral (ARV) drugs. Poly-L-lactic acid (PLLA) acid has been used to correct facial lipoatrophy in people with HIV since 2004 both in Europe and the United States. The objective of this study was to establish, in real life conditions and in a large sample, the safety of PLLA (New Fill®, Valeant US, Sinclair Pharma Paris, France) to correct facial lipoatrophy among HIV-positive patients. METHODS A longitudinal study was conducted between 2005 and 2008 in France. Data from 4,112 treatment courses (n = 4,112 patients) and 15,665 injections sessions (1 to 5 injection sessions per treatment course) were gathered by 200 physicians trained in the use of PLLA. RESULTS The average age of patients (88.3% males) treated for lipoatrophy was 47.1 ± 8.1 years (Mean ± SD); 91.2% of patients had been receiving ARV treatment for 10.9 (±4.2) years; CD4 T-cell count was 535 ± 266 cells/mm3. The duration of facial lipoatrophy was 5 ± 2.8 years and the severity was such that 47.3% of patients required five injection sessions of PLLA and 81.9% of the sessions required two vials of the preparation. The final visit, scheduled two months after the last injection session, was attended by 66.0% of patients (n = 2,713). 48 treatment courses (2.8%) were discontinued due to adverse events (AEs). The overall incidence of AEs per course was 18.8%. Immediate AEs, bleeding (3.4%), bruising (2.3%), pain (2.0%), redness at injection site (1.6%), and swelling of the face (0.7%), occurred in 15.4% of courses and 7.0% of sessions (usually during the first session). Non-immediate AEs, mainly nodules (5.7%), inflammation (0.7%), granuloma (0.3%), discolouration (0.2%), and skin hypertrophy (0.1%), occurred in 6.7% of courses. Non-immediate AEs occurred within a time ranging from 21 days (inflammation) to 101 days (granuloma) and all but three of the 13 cases of granuloma resolved. Product efficacy was rated satisfactory by 95% of the patients and physicians. CONCLUSIONS This study demonstrated, in real-life conditions and on a large sample, that PLLA injections were feasible, efficient, and safe when performed by trained physicians.
Collapse
Affiliation(s)
- Martin Duracinsky
- />Bicêtre Hospital, Internal Medicine and Clinical Immunology, University Paris Diderot, Sorbonne Paris Cité, EA REMES, Patient Reported Outcomes Unit, Paris, & AP-HP, Le Kremlin-Bicêtre Paris, France
| | - Pascale Leclercq
- />Grenoble University hospital, Michallon hospital, Information and Treatment Centres for Human Immunodeficiency, BP 217, 38043, CEDEX 09 Grenoble, France
| | - Susan Herrmann
- />Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia Australia
| | | | - Marc Dolivo
- />Association des Œuvres Sociales du Ministère des Affaires Etrangères, 57 Boulevard des Invalides, 75007 Paris, France
| | - Cécile Goujard
- />Bicêtre Hospital, Internal Medicine and Clinical Immunology, & University Paris Sud, Le Kremlin-Bicêtre Paris, France
| | - Olivier Chassany
- />Department of Clinical Research, University Paris Diderot, Sorbonne Paris Cité, EA REMES, Patient Reported Outcomes Unit & AP-HP, Saint-Louis Hospital, Paris, France
| |
Collapse
|
8
|
Quintas RCS, de França ER, de Petribú KCL, Ximenes RAA, Quintas LFFM, Cavalcanti ELF, Kitamura MAP, Magalhães KAA, Paiva KCF, Filho DBM. Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life. Int J Dermatol 2014; 53:497-502. [PMID: 24602032 DOI: 10.1111/ijd.12400] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The lipodystrophy syndrome is characterized by selective loss of subcutaneous fat on the face and extremities (lipoatrophy) and/or accumulation of fat around the neck, abdomen, and thorax (lipohypertrophy). The aim of this study has been to assess the impact of polymethylmethacrylate facial treatment on quality of life, self-perceived facial image, and the severity of depressive symptoms in patients living with HIV/AIDS. METHODS A non-randomized before and after interventional study was developed. Fifty-one patients underwent facial filling. The self-perceived quality of life, facial image, and degree of depressive symptoms were measured by the Short-Form 36 and HIV/AIDS--Targeted quality of life questionnaires, by a visual analogue scale and by the Beck depression inventory, respectively, before and three months after treatment. RESULTS Six of the eight domains of Short-Form 36 and eight of the nine dimensions of the HIV/AIDS--Targeted quality of life questionnaires, together with the visual analogue scale and by the Beck depression inventory scores, revealed a statistically significant improvement. The only adverse effects registered were edema and ecchymosis. CONCLUSION The treatment of facial lipoatrophy improved the self-perceived quality of life and facial image as well as any depressive symptoms among patients with HIV/AIDS.
Collapse
|
9
|
Marín A, Casado JL, Aranzabal L, Moya J, Antela A, Dronda F, Moreno A, Moreno S. Validation of a Specific Questionnaire on Psychological and Social Repercussions of the Lipodystrophy Syndrome in HIV-infected Patients. Qual Life Res 2013; 15:767-75. [PMID: 16721637 DOI: 10.1007/s11136-005-5001-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2005] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To validate a questionnaire to identify psychosocial repercussions of the lipodystrophy syndrome (LD) in HIV-infected patients. METHODS A questionnaire containing 35 items in 6 subscales [body image, anxiety, depression, social support, social distress, quality of life (QoL)] was consecutively administered to 128 patients with LD, 25 naive patients or on therapy without LD, and to 15 HIV negative patients from January to July '04. Reliability was assessed using Cronbach's alpha and the intraclass correlation coefficient (ICC). The area under the curve (AUC) was used for discrimination between patients and control groups, and the scores were compared according to the severity of the LD. RESULTS In all the subscales, the relationship between higher scores and LD severity was statistically significant (0.37-0.64, p<0.01), whereas the control groups had significantly lower scores. The internal consistency showed Cronbach's alpha coefficients ranging from 0.64 to 0.93. Test-retest reliability after 15 days in 30 patients showed ICC values of 0.8-0.94. AUC values for the different subscales were higher than 0.7 with the exception of QoL score, and construct validity showed a significant correlation with the Beck Depression Inventory and the MOS-HIV scores (0.49 and 0.51, respectively, p<0.01). CONCLUSIONS Our questionnaire shows satisfactory psychometric properties for identifying psychosocial repercussions of the LD in HIV-infected patients.
Collapse
Affiliation(s)
- Ana Marín
- Department of Infectious Diseases, Ramon y Cajal Hospital, 28034, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Plankey M, Bacchetti P, Jin C, Dass-Brailsford P, Gustafson D, Cohen M, Karim R, Yin M, Tien PC. The association of self-perception of body fat changes and quality of life in the Women's Interagency HIV Study. AIDS Care 2013; 25:1544-50. [PMID: 23656440 PMCID: PMC3769511 DOI: 10.1080/09540121.2013.793265] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Body fat changes are of concern to HIV-seropositive adults on highly active antiretroviral therapy (HAART). Studies examining the association of body fat changes and quality of life (QOL) in the setting of HIV infection have been conducted predominately in men. We examined the relationship of self-perceived body fat change with QOL among 1671 HAART-using HIV-seropositive women (mean age 40±8 years; 54% African-American, 24% reporting <95% HAART adherence) from the Women's Interagency HIV Study. Self-perception of any fat loss was associated with lower overall QOL. Report of any peripheral fat loss was strongly associated with nearly all QOL domains (i.e., physical functioning, role functioning, energy/fatigue, social functioning, pain, emotional well-being, health perception, and perceived health index) except cognitive functioning, whereas report of any central fat loss was significantly associated with lower social and cognitive functioning. Report of any central fat gain was associated with lower overall QOL, but only physical functioning, energy/fatigue, and cognitive functioning were significantly affected. A significant association of report of any peripheral fat gain with overall QOL was not observed, however, peripheral fat gain was significantly associated with lower physical functioning and pain. We found that any report of fat loss, especially in peripheral body sites was associated with lower QOL, as was any report of central fat gain. Ultimately health providers and patients need to be informed of these associations so as to better support HIV-seropositive women who live with these effects.
Collapse
Affiliation(s)
| | | | - Chengshi Jin
- University of California, San Francisco, CA, USA
| | | | | | - Mardge Cohen
- CORE Center Bureau of Health Services of Cook County, Chicago, IL, USA
| | - Roksana Karim
- Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Michael Yin
- Department of Medicine, Columbia University Medical Center, New York, NY, USA
| | - Phyllis C. Tien
- University of California, San Francisco, CA, USA
- Department of Veterans Affairs Medical Center, San Francisco, CA, USA
| |
Collapse
|
11
|
Leclercq P, Goujard C, Duracinsky M, Allaert F, L'Henaff M, Hellet M, Meunier JP, Carret S, Thevenon J, Ngo Van P, Pialoux G. High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy. AIDS Res Hum Retroviruses 2013; 29:761-8. [PMID: 23268562 DOI: 10.1089/aid.2012.0214] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Few data report the prevalence in actual clinical settings of lipodystrophy (LD), and in particular of facial lipoatrophy (LA), in HIV-infected patients treated with long-term antiretroviral therapy (ART). A French, multicenter, cross-sectional, observational study was conducted in HIV-infected patients on continuous ART for more than 12 months. The main objective was to assess the prevalence of facial LA in this population. Additional objectives were to make the same assessments for nonfacial LA and lipohypertrophy. The presence of LD signs, type, and severity was assessed by clinicians and compared with patient self-evaluations through two questionnaires. A total of 2,131 assessable patients had a median age of 46 years and a median time on ART of 10 years. Physicians diagnosed facial LA in 54% of patients and these subjects had received ART for a longer duration than those without LA. Thymidine analog usage was associated with an increased likelihood of facial LA, but 28% of patients recently treatment-initiated (1-5 years) were also affected. At other sites, LA and lipohypertrophy were diagnosed in 59% and 57% of cases, respectively. The concordance between physician and patient assessments was good for facial and buttocks LA. In this study, facial LA affects more than half of the subjects and is frequent even among the most recently treated patients. The prevalence of facial LA significantly increases with the duration of ART, with male gender, hepatitis C virus (HCV) coinfection, and non-African origin being independent risk factors. Lipohypertrophy is frequent and appears early after ART initiation.
Collapse
Affiliation(s)
| | - Cecile Goujard
- Hôpital Bicêtre (AP-HP), and Université Paris-Sud 11, Le Kremlin-Bicêtre, France
| | - Martin Duracinsky
- Hôpital Bicêtre (AP-HP), and Université Paris-Sud 11, Le Kremlin-Bicêtre, France
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Autologous Fat Grafting and Injectable Dermal Fillers for Human Immunodeficiency Virus–Associated Facial Lipodystrophy. Plast Reconstr Surg 2013; 131:499-506. [DOI: 10.1097/prs.0b013e31827c6df5] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use. BMC Infect Dis 2013; 13:92. [PMID: 23425246 PMCID: PMC3598243 DOI: 10.1186/1471-2334-13-92] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Accepted: 02/06/2013] [Indexed: 11/10/2022] Open
Abstract
Background Many HIV patients receiving antiretroviral treatment develop lipodystrophy. NEW-FILL® is a polylactic acid injected to treat facial lipoatrophy. The objectives of this study were to describe (1) change in quality of life (QoL) of HIV patients treated with NEW-FILL® in the management of facial lipoatrophy; (2) efficacy of NEW-FILL® using facial photographs and (3) a patient-reported “Overall Treatment Effect” (OTE) scale; and (4) safety of NEW-FILL®. Methods Doctors from 13 treatment centres recruited 230 HIV patients to receive up to 5 sessions of NEW-FILL® injections. Patients self-reported QoL with the ABCD questionnaire before the first set of injections, at 2 months and at 12 to 18 months after the last session of injections. Efficacy was evaluated at each interval through photographs and OTE scale. Safety was evaluated via Case Report Form (CRF) data. Results 64.4% of patients reported QoL improvements of >10% at 2 months, and 58.8% at 12–18 months. Lipoatrophy grades improved at each visit (“no lipoatrophy” or “limited lipoatrophy”: 20.3% at inclusion, 77.4% at 2 months, 58.4% at 12–18 months). Average OTE scores of 5.3 and 5.0 at 2 and 12–18 months indicated “moderate improvement”. Minimum Important Difference (MID) in QoL score was 7.1 points at 2 months; 7.4 points at 12–18 months. For 911 injection sessions performed, 3.4% resulted in “immediate” adverse events, 7% in “non-immediate” events, and 1.7% in “other” events. Conclusions Improvements to quality of life and diminished lipoatrophy visibility were observed in the months immediately following NEW-FILL® treatment and were maintained 12–18 months post-treatment. Most adverse events were mild and transient. ABCD MID thresholds provide clinicians with means to assess the impact of lipoatrophy therapies on QoL.
Collapse
|
14
|
Warde M, Gragnani A, Gomes H, Hochman B, Ferreira LM. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires. Int J STD AIDS 2012; 22:596-9. [PMID: 21998182 DOI: 10.1258/ijsa.2009.009086] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Life-expectancy increased in patients infected with HIV/AIDS with the advent of highly active antiretroviral therapy (ART). Facial lipoatrophy is a common complication in these patients, eventually leading to stigma, segregation and a negative impact in quality of life (QOL). We measured the impact of the treatment of facial lipoatrophy with polymethyl methacrylate (PMMA) in the QOL of patients with HIV/AIDS by using four questionnaires that address QOL. Forty consecutive patients on ART referred for facial lipoatrophy treatment were enrolled in this study. The first 20 were allocated to the intervention group and were treated with tissue augmentation with PMMA. The other 20 were allocated to the control group, which received treatment only after six months. At baseline, four questionnaires were applied to all patients in both groups and again after six months. The variation in scores within the control group for all domains of all four instruments was significantly better when compared with that within the control group. We detected improvement in the QOL of patients with HIV/AIDS and facial lipoatrophy when they were treated with PMMA.
Collapse
Affiliation(s)
- M Warde
- Division of Plastic Surgery, Federal University of Sao Paulo, São Paulo, Brazil
| | | | | | | | | |
Collapse
|
15
|
Facial lipoatrophy: appearances are not deceiving. J Assoc Nurses AIDS Care 2009; 20:169-75. [PMID: 19427594 DOI: 10.1016/j.jana.2009.01.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2008] [Accepted: 01/27/2009] [Indexed: 11/21/2022]
Abstract
Lipodystrophy syndrome (LS) has been reported as visible markers that can identify HIV status. Changes in body shape are detrimental in terms of psychological welfare and may affect well-being and increase the stigma associated with HIV disease. In the current study, the psychosocial impact of LS was evaluated. A total of 84 HIV-infected patients receiving antiretroviral therapy and exhibiting dyslipidemia were interviewed in an urban hospital setting in Brazil in 2006 using a standardized questionnaire. Of the 84 patients exhibiting dyslipidemia, 40 patients also exhibited body changes, and of these, 25 had facial lipoatrophy. From a psychosocial perspective, patients presenting with facial lipoatrophy reported alterations in self-image and self-esteem and believed that other people noticed their body changes. The results are relevant for nurses who need to be well-prepared to recognize lipodystrophy, to implement nursing interventions including lifestyle changes, and to provide psychosocial support to patients with LS.
Collapse
|
16
|
Hornberger J, Rajagopalan R, Shewade A, Loutfy M. Cost consequences of HIV-associated lipoatrophy. AIDS Care 2009; 21:664-71. [DOI: 10.1080/09540120802511851] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- J. Hornberger
- a Cedar Associates LLC , Menlo Park , USA
- b Stanford University , Stanford , CA , USA
| | - R. Rajagopalan
- c Abbott Laboratories , Global Health Economic and Outcomes research , Abbott Park , USA
| | - A. Shewade
- a Cedar Associates LLC , Menlo Park , USA
| | - M.R. Loutfy
- d Department of Medicine , University of Toronto , ON , Canada
| |
Collapse
|
17
|
Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. Alcohol 2009; 43:65-71. [PMID: 19185212 DOI: 10.1016/j.alcohol.2008.09.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2008] [Revised: 09/19/2008] [Accepted: 09/22/2008] [Indexed: 11/20/2022]
Abstract
Lipodystrophy is a common long-term complication of HIV infection that may lead to decreased quality of life and less adherence to antiretroviral therapy (ART). A complete understanding of the etiology of HIV-associated lipodystrophy has not yet been achieved, although factors related to the virus, per se, and use of ART appear to be related. Alcohol use is common among HIV-infected patients and has biological effects on fat distribution, yet alcohol's relationship to HIV-associated lipodystrophy has not been examined. The goal of this clinical study was to assess the effect of alcohol consumption on lipodystrophy in HIV-infected adults with alcohol problems. This was a prospective study (2001-2006) of 289 HIV-infected persons with alcohol problems. The primary outcome was self-reported lipodystrophy, which was assessed at one time point (median 29 months after enrollment). Alcohol use was assessed every 6 months and classified as: abstinent at all interviews; > or = 1 report of moderate drinking but no heavy drinking; 1 or 2 reports of heavy drinking; or > or = 3 reports of heavy drinking. Multivariable logistic regression models were fit to the data. Fifty-two percent (150/289) of subjects reported lipodystrophy. Alcohol consumption was: 34% abstinent at all interviews; 12% > or = 1 report of moderate drinking, but no heavy drinking; 34% 1-2 reports of heavy drinking; and 20% > or = 3 reports of heavy drinking. Although not statistically significant, subjects with alcohol use had a higher odds of lipodystrophy (adjusted odds ratios and 95% confidence interval: > or = 1 report of moderate drinking, 2.36 [0.89, 6.24]; 1-2 reports of heavy drinking, 1.34 [0.69, 2.60]; > or = 3 reports of heavy drinking, 2.07 [0.90, 4.73]). Alcohol use may increase the odds of developing HIV-associated lipodystrophy among subjects with alcohol problems. However, larger studies are needed to fully elucidate the role and impact of alcohol consumption on the development of this common long-term complication of HIV infection and its treatment.
Collapse
|
18
|
Mest DR, Humble GM. Retreatment with Injectable Poly-l-Lactic Acid for HIV-Associated Facial Lipoatrophy. Dermatol Surg 2009; 35 Suppl 1:350-9. [DOI: 10.1111/j.1524-4725.2008.01047.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
Alencar TMDD, Nemes MIB, Velloso MA. Transformações da "aids aguda" para a "aids crônica": percepção corporal e intervenções cirúrgicas entre pessoas vivendo com HIV e aids. CIENCIA & SAUDE COLETIVA 2008; 13:1841-9. [DOI: 10.1590/s1413-81232008000600019] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2006] [Accepted: 12/04/2006] [Indexed: 11/21/2022] Open
Abstract
Após dez anos de uso da terapia anti-retroviral de alta potência, um novo problema surge: a síndrome lipodistrófica do HIV, uma distribuição irregular de gordura no corpo, decorrente do uso das medicações anti-retrovirais. Se no início da epidemia, a aids era caracterizada, sobretudo, pela magreza, hoje - tempos de "aids crônica"- estamos, uma vez mais, diante do estigma sobre o corpo, só que, paradoxalmente, com sinal trocado - o acúmulo "desordenado" de gordura no corpo. Este artigo apresenta e compara as mudanças corporais percebidas por pessoas que vivem com HIV e aids, ocorridas nos últimos anos da epidemia, com a utilização dos anti-retrovirais. Foram analisadas 32 entrevistas qualitativas com pessoas vivendo com HIV e aids, realizadas nos anos de 1999 e 2005. Ao nos depararmos com as novas questões emergentes e analisarmos sua interação com a crescente disponibilidade e utilização de tecnologias, fica a forte sensação de ressurgimento, sob nova forma, dos mesmos paradoxos previamente existentes nos tempos da aids aguda: o impacto dos sinais e um certo tipo de ressurgimento da desesperança quanto ao futuro de vida dessas pessoas.
Collapse
|
20
|
Melchior R, Nemes MIB, Alencar TMD, Buchalla CM. [Challenges of treatment adherence by people living with HIV/AIDS in Brazil]. Rev Saude Publica 2008; 41 Suppl 2:87-93. [PMID: 18094791 DOI: 10.1590/s0034-89102007000900014] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2006] [Accepted: 07/06/2007] [Indexed: 11/21/2022] Open
Abstract
OBJECTIVE To analyze the difficulties related to treatment adherence by patients living with HIV/AIDS in highly active antiretroviral therapy. METHODS Qualitative research based on 34 interviews with patients under treatment in several outpatient services in the state of São Paulo, in 1998-1999. The group was comprised of people from different socioeconomic levels, gender, length of treatment and varied adherence levels, according to healthcare staff perception. The interviews focused on the patient's narrative about his/her disease. The content analysis classified the difficulties as follows: related to social factors and life styles, including the stigma; related to beliefs about the use of medication; and directly related to the use of medication. RESULTS All the interviewees reported having difficulties concerning the stigma of living with HIV/AIDS. The difficulties related to the use of medication were the most important among patients with the best adherence level. Patients with average adherence level presented all three types of difficulties. CONCLUSIONS Social and cultural factors are more difficult to be overcome in order to achieve treatment adherence than those related to taking medication, thus making the role played by the health sector important, supported by clear public social policies. These dimensions must be faced not only in the health sector, but also on social and political levels.
Collapse
|
21
|
Malacarne M, Cargnel A, Lucini D, Pizzinelli P, Porta A, Pagani M. Feasibility of assessing autonomic dysregulation at a distance: the case of the HIV-positive patient. Telemed J E Health 2008; 13:557-63. [PMID: 17999617 DOI: 10.1089/tmj.2006.0092] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Alterations in lipid metabolism are a possible consequence of highly active antiretroviral therapies (HAART) for human immunodeficiency virus (HIV)-positive patients with consequent increase of cardiovascular risk. In this context we hypothesized that both acquired immunodeficiency syndrome (AIDS) and HAART might be associated to alterations in autonomic cardiovascular regulation. In this preliminary investigation we enrolled a total of 66 men, subdivided in two groups, 33 HIV-positive patients, and 33 healthy controls, and we tested the hypothesis that heart rate variability (HRV) of HIV positive patients can be assessed with a transtelephonic approach from the HIV clinic: 100% of the total of electrocardiograms (ECG) recordings that were sent from the distant site were successfully received and analyzed. Evaluation of the signal was subsequently performed in the centralized laboratory, and consisted in extracting the RR interval variability (RRV) series and afterward subjecting it to autoregressive spectral analysis. This study shows the feasibility of obtaining, from personnel without specific training, adequate RR variability data for further spectral analysis form a distant specialized autonomic laboratory. This feature is of critical importance in the context of possible large-scale application of this simple telemedicine approach.
Collapse
Affiliation(s)
- Mara Malacarne
- Centro di Ricerca sulla Terapia Neurovegetativa, Dipartimento Scienze Cliniche L. Sacco, University of Milano, Milano, Italy
| | | | | | | | | | | |
Collapse
|
22
|
Behrens GMN. Treatment options for lipodystrophy in HIV-positive patients. Expert Opin Pharmacother 2007; 9:39-52. [DOI: 10.1517/14656566.9.1.39] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
23
|
Schreij G, Janknegt R. InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'. Expert Opin Pharmacother 2007; 8 Suppl 1:S37-47. [PMID: 17931077 DOI: 10.1517/14656566.8.s1.s37] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
InforMatrix is an interactive decision matrix technique. This paper describes the use of InforMatrix to determine an order of merit within the various nucleoside and nucleotide reverse transcriptase inhibitors. In the order of merit, six criteria (effectiveness, safety, tolerance, convenience, usability and costs) are weighted against each other. Data necessary for this weighting process are derived from literature as well as personal practical experience. This article gives an overview of the most relevant information from clinical trials, cohort studies and databases concerning backbones consisting of two nucleoside/nucleotide reverse transcriptase inhibitors in the treatment of HIV infections, as well as a description of the interactive decision matrix technique. By using this interactive matrix technique, a rational consideration of the treatment options for backbones consisting of two nucleoside/nucleotide reverse transcriptase inhibitors becomes possible.
Collapse
Affiliation(s)
- Gerrit Schreij
- University Hospital Maastricht, Maastricht, The Netherlands
| | | |
Collapse
|
24
|
Orlando G, Guaraldi G, De Fazio D, Rottino A, Grisotti A, Blini M, De Santis G, Pedone A, Spaggiari A, Baccarani A, Vandelli M, De Paola M, Comelli D, Nardini G, Beghetto B, Squillace N, Esposito R. Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study. AIDS Patient Care STDS 2007; 21:833-42. [PMID: 18240893 DOI: 10.1089/apc.2007.0029] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The aim of this observational, prospective, nonrandomized study was to assess long-term psychometric outcomes of surgical treatment of HIV-related facial lipoatrophy. Two hundred ninety-nine participants (70.8% male) consecutively attending the Metabolic Clinic of Modena and Reggio Emilia University from November 2005 to July 2006, undergoing surgical interventions for HIV-related facial lipoatrophy were enrolled. Fifty-four (18.1%) underwent facial lipofilling, which consists of the harvesting of a small, intact parcel of fatty tissue with processing that removes the nonviable components and of the transport of fatty parcels through a small cannula to implant the graft in a manner that provides nutrition and anchors the fat to the host tissue. After an initial lipofilling, 24 (8%) needed polylactic acid injections to correct cheek asymmetry, 91 (30.4%) received only polylactic acid infiltrations, and 130 (43.5%) polyacrylamide infiltrations only. Subjective outcome measures were face aesthetic satisfaction, body image perception, depression evaluated by a visual analogue scale (VAS), the Assessment of Body Change and Distress questionnaire (ABCD), and by the Beck Depression Inventory questionnaire, respectively. Objective measure was cheek thickness evaluated by a 7.5-MHz frequency ultrasound probe perpendicular to the skin surface at the nasolabial fold, the corner of the mouth, the zygomatic arch, and centrally between these points in the buccal fat pad area. Both subjective and objective variables were evaluated at baseline and 48 weeks after end of surgical treatment. All 299 participants had significant improvement of the aesthetic satisfaction for the face (VAS from 2.9 +/- 2.1 to 6.2 +/- 2.1, p < 0.0001), of body image satisfaction (ABCD question 7 from 3.8 +/- 1 to 3.1 +/- 1 p < 0.0001 and ABCD question 8 from 70.7 +/- 16.7 to 77.2 +/- 17.2 p < 0.0001), of depression score (Beck score from 11.4 +/- 8.3 to 9.4 +/- 7.8 p = 0.001). Participants experienced a significant augmentation of both cheeks' thickness (right cheek from 4.3 +/- 1.9 mm to 9.5 +/- 3 mm p < 0.0001, left cheek from 4.4 +/- 2 mm to 9.6 +/- 3.1 mm, p < 0.0001). Our data suggest that facial surgery is an important option in the treatment of HIV-related lipoatrophy as an integral part of the management of HIV infection, because of the important and lasting psychological benefits.
Collapse
Affiliation(s)
- G. Orlando
- Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy
| | - G. Guaraldi
- Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy
| | - D. De Fazio
- Plastic Surgery–San Raffaele Hospital, Casa di cura San Pio X, Milan, Italy
| | - A. Rottino
- Plastic Surgery–San Raffaele Hospital, Casa di cura San Pio X, Milan, Italy
| | - A. Grisotti
- Plastic Surgery–San Raffaele Hospital, Casa di cura San Pio X, Milan, Italy
| | - M. Blini
- Plastic Surgery–San Raffaele Hospital, Casa di cura San Pio X, Milan, Italy
| | - G. De Santis
- Plastic Surgery–Azienda Ospedaliera Policlinico, Modena, Italy
| | - A. Pedone
- Plastic Surgery–Azienda Ospedaliera Policlinico, Modena, Italy
| | - A. Spaggiari
- Plastic Surgery–Azienda Ospedaliera Policlinico, Modena, Italy
| | - A. Baccarani
- Plastic Surgery–Azienda Ospedaliera Policlinico, Modena, Italy
| | - M. Vandelli
- Psychosocial Service–Azienda Ospedaliera Policlinico, Modena, Italy
| | - M. De Paola
- Psychosocial Service–Azienda Ospedaliera Policlinico, Modena, Italy
| | - D. Comelli
- Psychosocial Service–Azienda Ospedaliera Policlinico, Modena, Italy
| | - G. Nardini
- Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy
| | - B. Beghetto
- Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy
| | - N. Squillace
- Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy
| | - R. Esposito
- Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
25
|
Reid C, Courtney M. A randomized clinical trial to evaluate the effect of diet on quality of life and mood of people living with HIV and lipodystrophy. J Assoc Nurses AIDS Care 2007; 18:3-11. [PMID: 17662919 DOI: 10.1016/j.jana.2007.05.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2006] [Indexed: 11/30/2022]
Abstract
The purpose of this study in 2002 was to evaluate a diet intervention in relation to the quality of life and mood of people living with HIV and lipodystrophy. HIV-positive people on antiretroviral treatments are normalizing their lives and facing a long-term future. Morphological changes in some cases may occur as a result of antiretroviral therapy, causing HIV-positive people to hesitate commencing treatment. The study sample consisted of 30 men over 18 years of age living with HIV and lipodystrophy. An experimental design incorporating pretests and posttests of experimental and control groups was used. All participants were surveyed by questionnaire, and their quality of life and mood were measured at baseline and 10 weeks. Results indicated a trend toward significant improvement in quality of life, and although mood states were not significantly improved between the two groups, the control group showed deterioration in mood status, compared with the intervention group, that was concluded to be clinically significant. Hence, in the study setting, the diet intervention showed a positive effect on men living with HIV and lipodystrophy.
Collapse
Affiliation(s)
- Carol Reid
- Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Austria
| | | |
Collapse
|
26
|
Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther 2007; 4:16. [PMID: 17634130 PMCID: PMC1988803 DOI: 10.1186/1742-6405-4-16] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Accepted: 07/16/2007] [Indexed: 12/28/2022] Open
Abstract
A segment of the HIV infected population develops abnormal and excessive accumulation of adipose tissue in the trunk, including accumulation of visceral (deep abdominal) adipose tissue. This condition, known as HIV-related adipose redistribution syndrome (HARS), may also be accompanied by fat accumulation in the upper back/neck (dorsocervical region) and/or depletion of subcutaneous adipose tissue from the abdomen, face, limbs, or buttocks. HARS is estimated to occur in up to 32% of patients and is associated with health risks similar to those of metabolic syndrome. Techniques to detect and measure HARS include physician and patient assessments and radiologic or anthropometric methods.
Collapse
Affiliation(s)
| | - Ashok Balasubramanyam
- Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX, USA
| | - Rajagopal Sekhar
- Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX, USA
| | | |
Collapse
|
27
|
Reid C, Courtney M. A randomized clinical trial to evaluate the effect of diet on weight loss and coping of people living with HIV and lipodystrophy. J Clin Nurs 2007; 16:197-206. [PMID: 17584429 DOI: 10.1111/j.1365-2702.2007.01915.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIM The purpose of the research study was to evaluate a diet intervention in relation to the perceived weight loss and ways of coping of people living with HIV and lipodystrophy. The objectives were (i) to measure the perceived impact of weight loss upon men with HIV and lipodystrophy following a diet intervention and (ii) to identify strategies used by men to cope with HIV and lipodystrophy following a diet intervention. BACKGROUND HIV positive people on antiretroviral treatments are normalizing their lives and are facing a life-long future. Morphological changes occur as a result of antiretroviral therapy causing HIV positive people to hesitate commencing treatment. DESIGN An experimental design incorporating pretests and posttests of experimental and control groups was used in the study. METHODS The sample consisted of 30 men over 18 years of age, living with HIV and lipodystrophy. All participants were surveyed by questionnaires and their perceived weight loss and ways of coping were measured at baseline and 10 weeks. RESULTS Findings indicated a significant improvement for perceived weight loss and although not significant, all coping processes were used more by the participants in the intervention group compared with the control group. CONCLUSIONS The diet intervention demonstrated a positive effect particularly upon perceived weight loss on men living with HIV and Lipodystrophy in the study setting. RELEVANCE TO CLINICAL PRACTICE Diet is a recommended management option for people who endure severe and distressing symptoms from antiretroviral therapy.
Collapse
Affiliation(s)
- Carol Reid
- Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, and Queensland University of Technology, Brisbane, QLD, Australia.
| | | |
Collapse
|
28
|
Keiser P, Nassar N. Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. Expert Opin Pharmacother 2007; 8:477-83. [PMID: 17309342 DOI: 10.1517/14656566.8.4.477] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Treatment of HIV infection has typically been carried out using two nucleoside analogs and a protease inhibitor. Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside-based regimens, can improve adherence and decrease toxicities associated with protease inhibitor therapy. A formulation of abacavir sulfate/lamivudine/zidovudine allows a dosing schedule of one pill twice daily. The components have performed favorably compared with protease inhibitor-based regimens, such as indinavir. Compared with efavirenz-based regimens, abacavir sulfate/lamivudine/zidovudine has not performed as well. The combination is being studied as a cornerstone for induction maintenance strategies, in which switching a patient to abacavir sulfate/lamivudine/zidovudine has been associated with similar virologic outcomes as continuing with either protease inhibitor- or efavirenz-based regimens. Administration of abacavir sulfate/lamivudine/zidovudine also avoids side effects of antiretroviral therapy, such as hyperlipidemia, but its use is associated with a hypersensitivity reaction in a small number of patients. The combination of abacavir sulfate/lamivudine/zidovudine is an important part of the HIV armamentarium. Its potency and ease of administration make it worth consideration in the treatment of HIV, either by itself or in combination with other agents.
Collapse
Affiliation(s)
- Philip Keiser
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | | |
Collapse
|
29
|
Mest DR, Humble G. Safety and Efficacy of Poly-l-lactic Acid Injections in Persons with HIV-Associated Lipoatrophy: The US Experience. Dermatol Surg 2006; 32:1336-45. [PMID: 17083585 DOI: 10.1111/j.1524-4725.2006.32303.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND With the introduction of highly active antiretroviral therapy (HAART), HIV/AIDS has become a more chronic disease. This increase in survival, however, has been accompanied by the occurrence of metabolic and morphologic changes known collectively as HIV-associated lipodystrophy. OBJECTIVE The objective was to evaluate the quantifiable improvement in facial wasting (lipoatrophy) after serial injections of poly-L-lactic acid (PLLA) as well as the long-term safety and durability of this material. METHODS AND MATERIALS A single-site, open-label study in which patients received up to six treatment sessions of injectable PLLA. Patients were followed for 12 months after treatment. Patients were evaluated for increase in total cutaneous thickness by skin calipers. Serial photographs and patient satisfaction and patient well-being questionnaires were undertaken throughout the study period. RESULTS Patients at the end of treatment exhibited a mean increase in skin thickness of 65.1% compared with baseline values. This correction was maintained throughout the 12-month follow-up period (68.8% at 6 months and 73% at 12 months). On a one to five scale, patient satisfaction was 4.5 at the end of treatment and increased to 4.8 at 12-month follow-up. No serious adverse events were reported. CONCLUSION PLLA is a safe and well-tolerated treatment option for HIV-associated lipoatrophy.
Collapse
Affiliation(s)
- Douglas R Mest
- Blue Pacific Aesthetic Medical Group, El Segundo, California 90245, USA.
| | | |
Collapse
|
30
|
Safety and Efficacy of Poly-L-lactic Acid Injections in Persons with HIV-Associated Lipoatrophy. Dermatol Surg 2006. [DOI: 10.1097/00042728-200611000-00004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Préau M, Bouhnik AD, Spire B, Leport C, Saves M, Picard O, Reynes J, Salmon D, Dellamonica P, Raffi F, Morin M, Aproco-Copilote E. Qualité de vie et syndrome lipodystrophique chez les patients infectés par le VIH. Encephale 2006; 32:713-9. [PMID: 17099595 DOI: 10.1016/s0013-7006(06)76223-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
AIM OF THE STUDY The aim of this work is to show to what extent a psychosocial evaluation can lead bring to comprehension of the subjectivity of Quality of Life (QoL) among HIV-infected patients. Evaluation of QoL makes it possible to understand the link between the therapeutic effectiveness and the subjective evaluation of the treatment, but also to estimate more precisely how people live and take their treatment in the context of HIV infection. METHOD This work confronts the variation of QoL with the variation of several social and psychosocial parameters identified as of the components of the system, which is the subjective evaluation, and more precisely to a specific side effect of Highly Active AntiRetroviral Therapies (HAART): lipodystrophy syndrome that consists in body fat redistribution. This side effect could consist in an accumulation of body fat, or a loss of body fat or a combination of both symptoms. The analysis was made on the data from APROCO-COPILOTE cohort composed of HIV-infected patients initiating HAART. RESULTS Among a sample of 706 patients follow-up for three years and with available QoL data, we identified the variations of QoL according to the variation of this specific side effect and according to gender. Results show that lipodystrophy syndrome has a determinant impact on QoL different among male and female patients. Adjusted on clinical and socio-demographic characteristics, impaired women's QoL is associated with accumulation of body fat and impaired men's QoL is associated with loss of body fat. CONCLUSION These results underline the role of body image on subjective evaluation of QoL. The analysis of empirical data made it possible to highlight the social implication of the evaluation of QoL from the role of the social support, patient-provider relationship and the social context.
Collapse
Affiliation(s)
- M Préau
- Equipe Psychologie Sociale de la Santé, Laboratoire de Psychologie Sociale, Université de Provence, Aix-en-Provence
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7:181-5. [PMID: 16494632 DOI: 10.1111/j.1468-1293.2006.00342.x] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE We evaluated the long-term safety and efficacy of injectable poly-L-lactic acid (PLLA) for the correction of facial lipoatrophy. METHODS This was a randomized, open-label, comparative, single-centre study of injected PLLA in patients with HIV-related facial lipoatrophy. Thirty subjects were randomized to immediate or delayed PLLA treatments, administered as three sets of bilateral injections, 2 weeks apart, into the deep dermis above the buccal fat pad. Week 24 results have been published previously (Moyle et al, HIV Medicine 2004, Vol. 5, pp. 82-87). Long-term efficacy was assessed at a recall visit using visual analogue scales (VASs) to record patient satisfaction, and by the Hospital Anxiety and Depression Scale (HADS). Patients also reported any adverse events (AEs) during the treatment period and at the recall visit. RESULTS Twenty-seven patients returned for the recall visit, a minimum of 18 months post final study treatment. Fourteen of these patients were excluded from the recall visit because of additional treatment with PLLA. Improvements in VAS scores for facial appearance were sustained from baseline to the recall visit in both randomization groups (P<0.05 and P<0.001). Trends in improvement in HADS scores were also noted, with patients in the delayed group experiencing significant improvements in depressive symptoms (P<0.05). One case of injection-site induration and nine cases of injection-site nodules were noted at the recall visit, none of which was described as serious or severe. CONCLUSIONS Physical and psychological benefits of PLLA are sustained over at least 18 months. Delayed AEs include mild nodularity at the treatment site.
Collapse
Affiliation(s)
- G J Moyle
- Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK.
| | | | | | | |
Collapse
|
33
|
Guaraldi G, Orlando G, Squillace N, De Santis G, Pedone A, Spaggiari A, De Fazio D, Vandelli M, De Paola M, Bertucelli C, Aldrovandi C, Nardini G, Beghetto B, Borghi V, Bertolotti M, Bagni B, Grazia Amorico M, Roverato A, Esposito R. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV CLINICAL TRIALS 2006; 7:97-106. [PMID: 16880166 DOI: 10.1310/eywj-8b5k-x7vq-9cpe] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Treatment for metabolic and morphologic alterations in HIV-related lipodystrophy include medical therapy, physical exercise, and surgical interventions. METHOD We assessed the efficacy and safety of a comprehensive multidisciplinary approach for treating morphological and metabolic alterations of the lipodystrophy syndrome in consecutive patients attending the Metabolic Clinic (MC) of the University of Modena and Reggio Emilia who had at least 2 evaluations over a 48-week period. 245 patients were evaluated: 143 (62.4%) were men, 74 (36.1%) presented with lipoatrophy, 10 (4.9%) with fat accumulation, 93 (45%) with mixed forms, 24 (11.3%) had hypercholesterolemia (LDL >160 mg/dL), 87 (38%) had hypertriglyceridemia (TG >150 mg/dL), 13 (5.7%) had diabetes (glucose >126 mg/dL), and 78 (44%) had insulin resistance (HOMA-IR >4). RESULTS At follow-up, a significant improvement was observed in both objective and subjective variables. Anthropometric improvement was observed in waist to hip ratio, waist circumference, and right and left cheek dermal thickness measurements. A nonsignificant improvement was observed in fat and lean regional mass by DEXA; CT showed improvement in visceral and subcutaneous adipose tissue. Glucose, HOMA-IR, total cholesterol, and APO B improved. Subjective variables improved in aesthetic satisfaction. CONCLUSION We conclude that the medical and surgical interventions proposed in this multidisciplinary therapeutic approach are efficacious and safe in the management of lipodystrophy.
Collapse
Affiliation(s)
- Giovanni Guaraldi
- Department of Medicine and Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, Open-Label, 18-Month Trial of Calcium Hydroxylapatite (Radiesse) for Facial Soft-Tissue Augmentation in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy: One-Year Durability. Plast Reconstr Surg 2006; 118:34S-45S. [PMID: 16936543 DOI: 10.1097/01.prs.0000234847.36020.52] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The objective was to evaluate the safety and effectiveness of soft-tissue augmentation of calcium hydroxylapatite (Radiesse) in patients with facial lipoatrophy secondary to human immunodeficiency virus disease. METHODS This 18-month, prospective, open-label, multicenter clinical trial of calcium hydroxylapatite for soft-tissue augmentation of patients with facial lipoatrophy enrolled 100 subjects (94 men and six women). RESULTS Correction of facial lipoatrophy was evaluated by comparing changes from baseline using the Global Aesthetic Improvement Scale, with confirmation using standardized photography. All 100 patients were determined to be improved or better at 3 months. Secondary effectiveness endpoints-improvement at 6 months on the scale and skin thickness measurements at 3 and 6 months-were also met. Twelve-month data and 18-month scale scores were also available. One hundred percent of assessable patients were rated as improved or better on the scale at every time point through 12 months; 91 percent were improved or better at 18 months. "Yes" responses to all patient satisfaction questions ranged from 97 percent to 100 percent at every evaluation through 12 months. In addition, skin thickness measurements at 12 months remained statistically better than those at baseline. Eighteen-month patient satisfaction and skin thickness measurements were not available at the time of submission. Adverse events reported through 12 months were generally mild (ecchymosis, edema, erythema, pain, and pruritus), not unexpected, and generally short in duration. Eighteen-month safety data were not available at the time of submission. CONCLUSIONS Radiesse is an appropriate and well-tolerated treatment for patients with facial lipoatrophy. It demonstrates an excellent safety profile, causes immediate augmentation of the soft tissues, and appears to provide relatively long-lasting improvement in appearance, with very high patient satisfaction.
Collapse
Affiliation(s)
- Stacey L Silvers
- Chelsea Eye and Cosmetic Surgery Associates, New York, NY 10011, USA
| | | | | | | |
Collapse
|
35
|
Abstract
BACKGROUND Interest in facial lipoatrophy (LA) has recently intensified; this phenomenon is linked to the rise in the number of people adversely affected by the condition as a side effect of antiretroviral treatment for HIV, combined with the growing number of cosmetic products that claim to be able to correct the appearance of LA. Despite growing awareness of the problem, there is at present no standard and accepted technique with which to assess the severity of LA. OBJECTIVE This review explores facial LA, the use of ultrasound in the evaluation of facial LA, its advantages and disadvantages, and will place the technique in the context of other means of assessing regional skin and fat thickness. METHOD Review of literature published on PubMed. RESULTS Ultrasound, as with any technique used to assess facial LA, is associated with distinct advantages and disadvantages. CONCLUSIONS Studies that use a number of different techniques to evaluate changes in dermal thickness provide the greatest insight into both perceived and actual changes in facial LA. Further investigation into the use of these techniques is warranted, along with a formal consensus of facial LA grades.
Collapse
|
36
|
Facial Lipoatrophy and the Place of Ultrasound. Dermatol Surg 2006. [DOI: 10.1097/00042728-200605000-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Guaraldi G, Orlando G, Murri R, Vandelli M, De Paola M, Beghetto B, Nardini G, Ciaffi S, Vichi F, Wu AW. Quality of Life and Body Image in the Assessment of Psychological Impact of Lipodystrophy: Validation of the Italian Version of Assessment of Body Change and Distress Questionnaire. Qual Life Res 2006; 15:173-8. [PMID: 16411042 DOI: 10.1007/s11136-005-8342-y] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2005] [Indexed: 11/28/2022]
Abstract
Lipodystrophy (LD) includes morphologic changes that are distressing to patients with HIV. We tested the validity of an Italian version of the Assessment of Body Change and Distress (ABCD) questionnaire and analysed its relationship to physical and mental aspects of Health-Related Quality of Life. Two hundred and fifty-two patients completed the questionnaires. Construct validity of the ABCD was tested against the MOS-HIV Health Survey, body mass-index (BMI) and CD4+ T-lymphocyte counts. Cronbach's alpha for the ABCD total score was 0.94. The ABCD showed the hypothesized moderate correlations to MOS-HIV scales and clinical variables. Preliminary evidence supports the reliability and validity of the Italian version of the ABCD in people with HIV and LD. This questionnaire may be useful to identify people experiencing greater impact of LD, or to evaluate the impact of interventions to treat LD such as plastic surgery.
Collapse
Affiliation(s)
- G Guaraldi
- Department of Medicine and Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. PHARMACOECONOMICS 2006; 24:751-65. [PMID: 16898846 DOI: 10.2165/00019053-200624080-00003] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
With the advent of highly active antiretroviral therapy (HAART), HIV-infected patients are living longer and are concerned not only with a treatment's ability to extend their life but also with the quality of the life they are able to lead. Regulatory authorities are also paying closer attention to the use of health-related quality-of-life (HR-QOL) measures in clinical trials and to the subsequent claims that are made based on the results. This paper reviews existing HR-QOL measures reported in the HIV/AIDS literature since 1990 and identifies those most worthy of consideration for use in future clinical trials.A comprehensive review following predefined selection criteria was conducted. Generic and HIV-targeted measures were assessed for content and practicality for the clinical trial setting. The generic measures were additionally reviewed for the ability to produce preference-based index scores and for the existence of normative general population data. Three generic and six HIV-targeted measures met these selection criteria and were then assessed more fully in terms of their development (HIV-targeted measures), psychometric properties and appropriateness for use in clinical trials.It was determined that each of the selected generic measures (i.e. Medical Outcomes Study [MOS] 36-Item Short Form Survey Instrument [SF-36], EQ-5D, Health Utilities Index [HUI]) could serve as a useful adjunct to an HIV-targeted measure in a trial. The Functional Assessment of HIV Infection (FAHI) and MOS-HIV health survey were deemed the two most appropriate HIV-targeted measures. Each of the measures can be self-administered in < or = 10 minutes and there was ample evidence of their excellent psychometric properties. However, they would not be optimal in all HIV-infected subgroups (e.g. treatment naive vs advanced; adolescents vs older adults) targeted for clinical trial interventions. Although there is no one best HR-QOL measure for use in HIV/AIDS clinical trials, based on our review criteria we identified three generic and two HIV-targeted candidate measures. However, these measures have their limitations and it is clear that greater consensus needs to develop regarding more effective and efficient approaches to HR-QOL measurement in HIV/AIDS clinical trials. Along with the increasingly complex HR-QOL measurement task resulting from changes in the HIV-infected population and shifts in the HR-QOL burden associated with HIV infection and its treatment over the past 25 years, it is increasingly important that HR-QOL outcomes become viable endpoints in HIV/AIDS clinical trials.
Collapse
|
39
|
Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 2005; 19 Suppl 4:S14-21. [PMID: 16249648 DOI: 10.1097/01.aids.0000191485.92285.c7] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Highly active antiretroviral therapy has brought about a substantial improvement in the prognosis of HIV/AIDS. In this context, therapy-related body changes (lipodystrophy) gain in importance, in light of the psychological distress they cause and of their association with adherence to treatment. This study analyses patients' self-perception of central fat gain (CFG) and peripheral fat loss (PFL). METHODS A total of 457 patients were interviewed in a university outpatient facility for the treatment of adults and adolescents with HIV/AIDS in the city of São Paulo, Brazil, between September and December 2001. RESULTS Two-thirds of subjects (64.3%) perceived body changes. The self-perception of CFG and PFL was associated with greater schooling. The self-perception of CFG was more frequent among women and in patients who used protease inhibitors for longer periods. The self-perception of PFL was more frequent among older patients, patients who used stavudine for longer periods, and patients who reported a lack of adherence to antiretroviral agents. The quality of affective/social relationships with friends and family was inversely associated with the self-perception of PFL. CONCLUSION The evaluation of self-perceived body changes and their determinants in individuals living with HIV/AIDS may help improve provided care. Listening to what patients have to say concerning antiretroviral therapy-related body changes and how they perceive them, as well as including the patient in therapeutic decisions in this regard will contribute towards greater adherence to proposed interventions and towards an improvement in the quality of life.
Collapse
Affiliation(s)
- Claudia Paula Santos
- Casa da AIDS, Hospital das Clinicas, School of Medicine, University of São Paulo, Brazil
| | | | | | | | | | | |
Collapse
|
40
|
Burgoyne R, Collins E, Wagner C, Abbey S, Halman M, Nur M, Walmsley S. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res 2005; 14:981-90. [PMID: 16041895 DOI: 10.1007/s11136-004-2580-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To investigate the relationship between lipodystrophy-specific symptom severity and wellbeing. METHODS HIV-positive adult patients with body fat redistribution (lipodystrophy syndrome) associated with antiretroviral therapy reported their total non-lipodystrophy symptoms and side effects and completed measures assessing body fat changes (yielding Atrophy, Hypertrophy and Total Lipodystrophy scores), mental health and quality of life. Effects of total symptom complex and lipodystrophy severity on quality of life and mental health were analyzed using Spearman's rho correlations. Logistic regression analyses were utilized to determine the relative-odds of depression produced by overall symptom count and lipodystrophy score increments. RESULTS Mean ratings for Hypertrophy and Atrophy corresponded to 'very mild' and 'mild' degrees of severity, respectively. The total symptom complex was associated with ratings for most of the mental health and quality of life measures. Patient-perceived body image scores were the sole study variable responsive to lipodystrophy severity ratings. In comparison to reference norms, a pronounced degree of body image impairment was evident. CONCLUSION Although responsive to the total symptom profile, psychosocial measures typically utilized for evaluating quality of life and mental health status in HIV disease lacked sensitivity and specificity for measuring the consequences of lipodystrophy-associated fat distribution changes alone. Lipodystrophy severity did impact negatively on body image.
Collapse
Affiliation(s)
- Robert Burgoyne
- Toronto General Hospital Immunodeficiency Clinic, Ontario, Canada.
| | | | | | | | | | | | | |
Collapse
|
41
|
Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM, Podzamczer D. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19:917-25. [PMID: 15905672 DOI: 10.1097/01.aids.0000171405.46113.bf] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir. DESIGN AND METHODS NEFA was a randomized study designed to compare the efficacy of nevirapine, efavirenz or abacavir as substitutes for PI. A subset of 90 patients [abacavir (n = 29), efavirenz (n = 32), nevirapine (n = 29)] formed the metabolic study. Fasting total cholesterol (TC), high density lipoprotein cholesterol (HDL-c) and triglycerides levels were determined. Glucose homeostasis parameters were also collected. Lipodystrophy was evaluated by clinical examination and morphological measurements. RESULTS Treatment simplification led to overall lipid profile improvements. At 24 months, the two non-nucleoside reverse transcriptase inhibitors produced similar lipid benefits: HDL-c levels increased [efavirenz, 15% (P = 0.001); nevirapine, 21% (P < 0.001)] and TC to HDL-c ratios decreased [efavirenz, 14% (P < 0.001); nevirapine, 19% (P < 0.01)], an effect not observed in the abacavir arm. Non-HDL-c levels decreased by 10% in both the abacavir (P = 0.001) and efavirenz (P < 0.05) arms. Significant decreases in the levels of triglycerides occurred for the first year in all treatments; however, at 24 months most of the initial loss had been regained. Patients with baseline moderate or severe lipodystrophy obtained less-pronounced lipid benefits. Several insulin resistance markers showed a trend towards improvement. Conversely, no improvements in morphological abnormalities were observed. CONCLUSIONS Replacing PI with efavirenz, nevirapine or abacavir improved the lipid profile, with more marked results in non-lipodystrophic patients. In contrast, this strategy does not seem to be effective for reversing body fat abnormalities.
Collapse
Affiliation(s)
- Cesar Fisac
- Nutrition Section, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-Miguel MJ, De José Gómez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005; 164:271-6. [PMID: 15650834 DOI: 10.1007/s00431-004-1610-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2004] [Revised: 11/25/2004] [Accepted: 11/29/2004] [Indexed: 10/25/2022]
Abstract
UNLABELLED In this study we assessed the prevalence of fat redistribution and metabolic disorders in a population of HIV-infected children on antiretroviral treatment. To make associations with epidemiological parameters, clinical-immune status, viral load and highly active antiretroviral therapy (HAART), we performed a cross-sectional study in HIV-infected children. Epidemiological parameters (age, sex, family history), clinical and immune status, viral load, and duration of antiretroviral treatment (ART) and HAART, including protease inhibitors, were recorded. Presence of clinical signs of fat redistribution and lipid, glucose and lactic acid levels were evaluated. A total of 56 HIV-infected children, including 30 boys (54%), aged between 21 months and 18 years (mean 9.5 years) were studied. In all, 49 patients (87.5%) were receiving ART (mean duration 4 years) and 43 (77%) were receiving HAART (mean duration 3.6 years). Fat redistribution or lipodystrophy was present in 14 patients (25%); seven had lipohypertrophy (12.5%), two lipoatrophy (3.5%) and five a mixed pattern (8.9%). Fat redistribution was higher in children older than 11 years (50%). Of the lipodystrophic patients, 71.4% presented hypertriglyceridaemia (> 130 mg/dl) and 57% hypercholesterolaemia (> 180 mg/dl). We found significant associations between lipodystrophy and age, ART and HAART duration and hypertriglyceridaemia ( P < 0.001, 0.002, 0.016 and < 0.001, respectively), but no significant association with sex, family history, clinical or immune status and viral load. CONCLUSION The prevalence of lipodystrophy was 25% (95% confidence interval 14.8-34.6) with lipohypertrophy being the commonest pattern. Clinical fat redistribution was significantly associated with older age, duration of antiretroviral treatment and highly active antiretroviral therapy and hypertriglyceridaemia.
Collapse
Affiliation(s)
- Ana María Sánchez Torres
- Department of Paediatrics, Division of Infectious Diseases, La Paz Children's Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
Background The volume and anatomical distribution of facial fat depletion in HIV related lipoatrophy have not been properly quantified. We aimed to determine the extent and distribution of facial fat loss in HIV-infected patients with lipoatrophy and whether this differs from wasting. Design We studied HIV-infected patients with clinically defined moderate to severe lipoatrophy without wasting ( n=15), clinically defined wasting (>10% weight loss and recent opportunistic infection) with no previous reported lipodystrophy ( n=15), and controls without lipodystrophy or wasting ( n=15). Facial MRI scans were performed, and areas of fat were manually traced bilaterally in all individual image slices and summed to calculate volume in anatomically defined regions of interest. Results Patients with lipoatrophy had lower fat volumes in the temporal region (8.9 ±9.4 vs 20.5 ±7.2ml; P<0.001), cheek region (25.6 ±24.9 vs 55.5 ±15.0 ml; P<0.001), periorbital region (1.9 ±1.0 vs 2.7 ±1.0 ml; P=0.09) and buccal fat pad (13.4 ±9.4 vs 21.8 ±9.8 ml; P=0.030) compared with controls. Patients with wasting had temporal, cheek, periorbital and buccal fat pad volumes (10.4 ±6.7 ml, 34.0 ±14.8 ml, 1.4 ±1.1 ml and 13.1 ±4.6 ml respectively) that were lower than controls (all P<0.01) but similar to lipoatrophy patients (all P>0.5). Conclusions Facial fat depletion in lipoatrophy is substantial (approximately 50% volume loss) and involves superficial and deep fat (buccal fat pad). The distribution and volume of fat change is similar to that seen in wasting. Given the extent of the changes, complete surgical correction is unlikely to be possible and hence emphasis should be placed on prevention of
Collapse
Affiliation(s)
- Yong Yang
- Infectious Disease Research Centre (IDRC), Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
| | - Yih-Yian Sitoh
- Department of Neuroradiology, National Neuroscience Institute, Singapore
| | - Naing Oo Tha
- Infectious Disease Research Centre (IDRC), Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
| | - Nicholas I Paton
- Infectious Disease Research Centre (IDRC), Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
- HIV division, MRC Clinical Trials Unit, London, UK
| |
Collapse
|
44
|
Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina JM. Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in HIV-Infected Patients. J Acquir Immune Defic Syndr 2005; 38:393-8. [PMID: 15764955 DOI: 10.1097/01.qai.0000152834.02912.98] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND This study assessed the safety and efficacy of intradermal injections of polylactic acid (PLA) in patients with facial lipoatrophy under antiretroviral therapy. METHODS In a prospective open-label study, PLA was injected in both cheeks every 2 weeks. The primary efficacy endpoint was the patient's self-perception of improvement as assessed by a visual analogue scale (VAS). Secondary endpoints included 3-dimensional photographs (3DP) to measure dermal thickness, quality of life (QoL) scores, and adverse events. RESULTS Ninety-four patients received a median of 5 sets of injection in both cheeks. Median age was 43 years, and median CD4 cell count was 500/mm3. Median VAS score significantly increased from 3.4/10 at baseline to 6.8/10 at the end of the treatment procedure and was sustained at 7/10 at the end of follow-up (P < 0.0001 vs. baseline). Median dermal thickness increase was 2.3 mm at the end of follow-up. QoL scores remained unchanged. Seventeen patients needed further injections of PLA during a median follow-up of 12 months. Injections were well tolerated with only 1 serious adverse event (anaphylactic reaction) that necessitated treatment interruption. CONCLUSIONS Injections of PLA improved patients' self-perception of facial lipoatrophy, with a good safety profile. The benefit of the procedure, however, decreased with time.
Collapse
Affiliation(s)
- Matthieu Lafaurie
- Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | |
Collapse
|
45
|
Gooderham M, Solish N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg 2005; 31:104-8. [PMID: 15720106 DOI: 10.1111/j.1524-4725.2005.31020] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Lipodystrophy syndrome is a devastating complication of antiretroviral therapy in individuals with human immunodeficiency virus (HIV). The appearance of the associated facial lipoatrophy can be demoralizing and stigmatizing for the affected individuals to a point at which it may compromise their compliance with antiretroviral medication. OBJECTIVE We describe the use of hyaluronic acid as an intradermal filler for correction of this disfiguring problem. METHODS We treated five patients with grade 2 to 3 facial lipoatrophy. Each patient received approximately 5 to 6 cc in total of hyaluronic acid in the malar area via intradermal injection. RESULTS There were no adverse events. We found that this technique provided a good cosmetic result with high patient satisfaction. At 6-month follow-up, sustained longevity was observed. CONCLUSIONS We propose the use of hyaluronic acid for HIV-associated facial lipoatrophy as an efficacious and safe, but temporary, option for this problem until a more cost-effective option is available.
Collapse
Affiliation(s)
- Melinda Gooderham
- Department of Dermatology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario
| | | |
Collapse
|
46
|
Johnson MO, Charlebois E, Morin SF, Catz SL, Goldstein RB, Remien RH, Rotheram-Borus MJ, Mickalian JD, Kittel L, Samimy-Muzaffar F, Lightfoot MA, Gore-Felton C, Chesney A. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage 2005; 29:193-205. [PMID: 15793937 DOI: 10.1016/j.jpainsymman.2004.05.005] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Adverse effects from antiretroviral therapy (ARV) for HIV are associated with medication nonadherence. The purposes of this study were to explore group differences in the reporting of adverse effects, identify individual adverse effects that are linked to nonadherence, and to explore the role of coping in the relationship between adverse effects and adherence. Cross-sectional interviews of 2,765 HIV-positive adults on ARV therapies in four U.S. cities were performed using a computerized assessment of self-reported adverse effects, coping self-efficacy, and adherence. There were no gender differences in the rate or severity of adverse effects reported. Latino respondents reported more adverse effects than either White or African Americans. Those taking a protease inhibitor (PI) reported a higher rate and greater severity of adverse effects. Older participants reported fewer adverse effects despite being more likely to be on a regimen containing a PI. Respondents with less than 90% adherence reported greater numbers and severity of adverse effects overall. In multivariate analyses, nausea, skin problems, vomiting, and memory adverse effects were independently related to less than 90% adherence over the prior three days. Coping moderated the relationship between nausea and adherence such that individuals who reported lower coping self-efficacy and experienced nausea were at increased risk for nonadherence, regardless of the length of time on the current ARV regimen. Women and men are similar in their overall reports of adverse effects, and Latinos report more adverse effects to ARVs than White or African American patients. Specific adverse effects (skin problems, memory problems, vomiting, and nausea) are more likely than others to be associated with missing ARV medications. Increasing adaptive coping self-efficacy among patients experiencing nausea may be a particularly effective strategy in increasing medication adherence.
Collapse
Affiliation(s)
- Mallory O Johnson
- Center for AIDS Prevention Studies, University of California, San Francisco, 74 New Montgomery, Suite 600, San Francisco, CA 94105, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Norris A, Dreher HM. Lipodystrophy Syndrome: The Morphologic and Metabolic Effects of Antiretroviral Therapy in HIV Infection. J Assoc Nurses AIDS Care 2004; 15:46-64. [PMID: 15538016 DOI: 10.1177/1055329004271187] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Widespread use of highly active antiretroviral therapy (HAART) to manage HIV infection is now associated with the development of lipodystrophy syndrome. This syndrome is a combination of such morphologic and metabolic changes as hyperlipidemia, fat redistribution, and insulin resistance. Although many of the long-term effects of HAART have not been fully recognized, it is thought that lipodystrophy syndrome may now contribute to early-onset hypercholesterolemia, heart disease, and diabetes, and may have a negative psychological impact on the individual living with HIV infection.
Collapse
Affiliation(s)
- Angela Norris
- Partnership Comprehensive Care Practice HIV Clinic, Drexel University, Philadelphia, PA, USA
| | | |
Collapse
|
48
|
Evans A, Lee R, Mammen-Tobin A, Piyadigamage A, Shann S, Waugh M. HIV revisited: the global impact of the HIV/AIDS epidemic. Skinmed 2004; 3:149-56. [PMID: 15133394 DOI: 10.1111/j.1540-9740.2004.02304.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
This review is intended as an update on modern trends in the global impact and epidemiology of human immunodeficiency virus infection for physicians who are not acquired immunodeficiency syndrome experts. Africa has been the most affected, but epidemics are spreading in Asia and Russia. Therefore, physicians should be informed about seroconversion disease and human immunodeficiency virus diagnosis as well as the impact of sexually transmitted infections on many stages of human immunodeficiency virus. International treatment guidelines are available. Highly active antiretroviral therapy has been the mainstream therapy since 1996, but all drugs--regardless of class used--have potent side effects, many of which are dermatologic. Others affect the neurologic, hematopoietic, cerebral, and abdominal systems, and drug interactions are common. Lipodystrophy is a common, long-term side effect that is still not well understood. Broader use of highly active antiretroviral therapy has highlighted viral resistance. This is reviewed, and a simple explanation of therapeutic monitoring is provided.
Collapse
Affiliation(s)
- Amy Evans
- Department of Genitourinary Medicine, General Infirmary and University of Leeds, Leeds LS1 3EX, England
| | | | | | | | | | | |
Collapse
|
49
|
Orentreich D, Leone AS. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatol Surg 2004; 30:548-51. [PMID: 15056149 DOI: 10.1111/j.1524-4725.2004.30175.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Patients infected with the HIV may experience HIV-associated lipodystrophy, a symptom of which is facial lipoatrophy, a dramatic loss of subcutaneous facial tissue. This visible manifestation of HIV infection causes significant psychosocial pain for patients and has been associated with impaired compliance with medical regimens. OBJECTIVE To improve the appearance of facial lipoatrophy in a safe, long-lasting, expeditious, and relatively economical manner. METHODS An HIV-associated lipodystrophy patient with facial lipoatrophy underwent multiple sessions of soft-tissue augmentation therapy with liquid injectable silicone (LIS) using the microdroplet serial puncture technique. RESULTS Administration of LIS by the microdroplet serial puncture technique produced satisfactory improvement of areas of facial atrophy. The treatment time is limited, the patient discomfort and morbidity are minimal, and results are long lasting. Patients report significant satisfaction with treatment. CONCLUSION LIS administered by the microdroplet serial puncture technique is a safe and effective method for treating HIV-associated facial lipoatrophy and compares favorably with other methods of tissue augmentation.
Collapse
Affiliation(s)
- David Orentreich
- Orentreich Medical Group, LLP, Orentreich Foundation for the Advancement of Science Inc., 910 Fifth Avenue, New York, NY 10021, USA
| | | |
Collapse
|
50
|
Blanch J, Rousaud A, Martinez E, De Lazzari E, Milinkovic A, Peri JM, Blanco JL, Jaen J, Navarro V, Massana G, Gatell JM. Factors Associated with Severe Impact of Lipodystrophy on the Quality of Life of Patients Infected with HIV-1. Clin Infect Dis 2004; 38:1464-70. [PMID: 15156486 DOI: 10.1086/383573] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2003] [Accepted: 12/21/2003] [Indexed: 11/04/2022] Open
Abstract
A standardized questionnaire was used to assess the impact of lipodystrophy (LD) on quality of life (QoL). Eighty-four consecutive asymptomatic human immunodeficiency virus type 1 (HIV-1)-infected outpatients with clinical LD completed a modified version of the Dermatology Life Quality Index (DLQI) survey to measure the impact of body fat changes on their QoL. Body changes influenced dressing for 55 patients (65%), produced feelings of shame for 41 (49%), and disrupted sexual life for 23 (27%). There was a greater impact on the DLQI due to body changes among women, injection drug users, patients with abdominal or breast lipoaccumulation, and patients with a high number of non-LD side effects. Multivariate proportional odds model analysis showed that the severity of non-LD-associated side effects and the presence of breast lipoaccumulation were associated with impaired psychosocial functioning. Specific characteristics of patients, antiretroviral-based side effects, and breast lipoaccumulation exert a greater impact on QoL in HIV-1-infected patients with LD.
Collapse
Affiliation(s)
- Jordi Blanch
- Clinical Institute of Psychiatry and Psychology, Hospital Clínic Universitari de Barcelona, 08036 Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|